Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 94.5% in January

Generation Bio Co. (NASDAQ:GBIO) saw a significant decrease in short interest in January. As of January 15th, there was short interest totaling 2,068 shares, a decrease of 94.5% from the December 31st total of 37,732 shares. Based on an average daily trading volume, of 59,001 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are sold short. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 59,001 shares, the short-interest ratio is currently 0.0 days.

Generation Bio Stock Performance

Generation Bio stock traded down $0.09 during midday trading on Wednesday, reaching $5.58. 69,226 shares of the company were exchanged, compared to its average volume of 98,396. Generation Bio has a 1 year low of $3.00 and a 1 year high of $9.02. The firm’s 50-day simple moving average is $5.44 and its 200-day simple moving average is $5.55. The company has a market capitalization of $37.60 million, a price-to-earnings ratio of -0.60 and a beta of 2.05.

Generation Bio (NASDAQ:GBIO) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($3.18) by $2.36. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%.The business had revenue of $1.59 million during the quarter, compared to the consensus estimate of $0.66 million. On average, analysts forecast that Generation Bio will post -1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on GBIO shares. Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price on shares of Generation Bio in a report on Friday, November 7th. Jefferies Financial Group lowered Generation Bio from a “buy” rating to a “hold” rating and dropped their target price for the company from $11.00 to $5.00 in a research report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd. Wedbush set a $5.50 price objective on shares of Generation Bio and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Finally, Zacks Research upgraded Generation Bio to a “hold” rating in a research report on Monday. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.88.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC increased its holdings in shares of Generation Bio by 54.3% in the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after buying an additional 407,843 shares in the last quarter. Militia Capital Partners LP bought a new position in shares of Generation Bio in the second quarter worth about $174,000. Y Intercept Hong Kong Ltd bought a new stake in Generation Bio during the 2nd quarter worth about $47,000. Marshall Wace LLP acquired a new position in Generation Bio in the second quarter valued at about $37,000. Finally, Cantor Fitzgerald L. P. bought a new stake in shares of Generation Bio in the 3rd quarter valued at $606,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.